Vanderbilt researchers are looking to mRNA populations in podocytes — kidney cells that help filter blood — to help identify potential targets for treating diabetic kidney disease.

For patients with type 2 diabetes treated with basal or long-acting insulin, the use of continuous glucose monitors (CGMs) can result in significantly lower hemoglobin A1C (a blood test that reflects average blood glucose levels over three months), and better management of the disease according to a study recently published in the journal JAMA.

Vanderbilt researchers dissected the complex microenvironment of the pancreatic islet to discover the signals that drive beta cell regeneration — as a possible treatment for diabetes.

In HIV-positive individuals with diabetes, immune cells in fat are more proinflammatory and cytotoxic and may represent a therapeutic target for diabetes.

Disrupting the action of glucagon — a pancreatic hormone that works to raise blood glucose — restores functional insulin-producing cells in mouse models of type 1 diabetes and may be a promising treatment strategy.

Genetic variation that impacts glucose- and insulin-related signaling affects responses to type 2 diabetes treatments and warrants further study.

COVID-19 has been linked to cases of new-onset diabetes, diabetes-related emergencies and a higher death rate among diabetes patients.